<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asia Pac Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Asia Pac Psychiatry</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1758-5872</journal-id><journal-id journal-id-type="publisher-id">APPY</journal-id><journal-title-group><journal-title>Asia-Pacific Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1758-5864</issn><issn pub-type="epub">1758-5872</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27020720</article-id><article-id pub-id-type="pmc">5071681</article-id><article-id pub-id-type="doi">10.1111/appy.12238</article-id><article-id pub-id-type="publisher-id">APPY12238</article-id><article-id pub-id-type="other">APPSY-15-126.R5</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8&#x02010;week, prospective, open&#x02010;label, multicenter, single&#x02010;arm study</article-title><alt-title alt-title-type="right-running-head">Amilsulpride in Chinese patients</alt-title><alt-title alt-title-type="left-running-head">Y. Liang <italic>et al.</italic></alt-title></title-group><contrib-group><contrib id="appy12238-cr-0001" contrib-type="author"><name><surname>Liang</surname><given-names>Ying</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="appy12238-cr-0002" contrib-type="author"><name><surname>Cao</surname><given-names>Changan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="appy12238-cr-0003" contrib-type="author"><name><surname>Zhu</surname><given-names>Cheng</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="appy12238-cr-0004" contrib-type="author"><name><surname>Wang</surname><given-names>Chuanyue</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="appy12238-cr-0005" contrib-type="author"><name><surname>Zhang</surname><given-names>Congpei</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="appy12238-cr-0006" contrib-type="author"><name><surname>Dong</surname><given-names>Fang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="appy12238-cr-0007" contrib-type="author"><name><surname>Yang</surname><given-names>Fude</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="appy12238-cr-0008" contrib-type="author"><name><surname>Deng</surname><given-names>Hong</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="appy12238-cr-0009" contrib-type="author"><name><surname>Yu</surname><given-names>Jingjie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="appy12238-cr-0010" contrib-type="author"><name><surname>Tang</surname><given-names>Jisheng</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="appy12238-cr-0011" contrib-type="author"><name><surname>Su</surname><given-names>Lei</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="appy12238-cr-0012" contrib-type="author"><name><surname>Xin</surname><given-names>Limin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="appy12238-cr-0013" contrib-type="author"><name><surname>Hong</surname><given-names>Ling</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="appy12238-cr-0014" contrib-type="author"><name><surname>Gao</surname><given-names>Minglong</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="appy12238-cr-0015" contrib-type="author"><name><surname>Tang</surname><given-names>Muni</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="appy12238-cr-0016" contrib-type="author"><name><surname>Xie</surname><given-names>Shiping</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="appy12238-cr-0017" contrib-type="author"><name><surname>Lu</surname><given-names>Shuiping</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="appy12238-cr-0018" contrib-type="author"><name><surname>Liu</surname><given-names>Tiebang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="appy12238-cr-0019" contrib-type="author"><name><surname>Xu</surname><given-names>Xiaojin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="appy12238-cr-0020" contrib-type="author"><name><surname>Wang</surname><given-names>Xijin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="appy12238-cr-0021" contrib-type="author"><name><surname>Li</surname><given-names>Xuanzi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="appy12238-cr-0022" contrib-type="author"><name><surname>Wang</surname><given-names>Xueyi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="appy12238-cr-0023" contrib-type="author"><name><surname>Li</surname><given-names>Yi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="appy12238-cr-0024" contrib-type="author"><name><surname>Zhang</surname><given-names>Yong</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="appy12238-cr-0025" contrib-type="author"><name><surname>Chen</surname><given-names>Zhiyu</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="appy12238-cr-0026" contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Xin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="appy12238-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="appy12238-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">National Clinical Research Center for Mental Disorders</named-content><institution>Peking University Sixth Hospital, Institute of Mental Health, and the Key Laboratory of Mental Health, Ministry of Health, Peking University</institution><named-content content-type="city">Beijing</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Shenzhen Kangning Hospital</institution><named-content content-type="city">Shenzhen</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>The Seventh People Hospital of Hangzhou</institution><named-content content-type="city">Hangzhou</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Psychiatry, Beijing An Ding Hospital</named-content><institution>Capital Medical University</institution><named-content content-type="city">Beijing</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>The First Special Hospital of Harbin</institution><named-content content-type="city">Harbin</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Beijing Huilongguan Hospital</institution><named-content content-type="city">Beijing</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Psychiatry, West China Hospital</named-content><institution>Sichuan University</institution><named-content content-type="city">Chengdu</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Tianjin Anding hospital</institution><named-content content-type="city">Tianjin</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Mental Health Centre of Shandong Province</institution><named-content content-type="city">Jinan</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0010"><label><sup>10</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>The First Hospital of Hebei Medical University</institution><named-content content-type="city">Shijiazhuang</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0011"><label><sup>11</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Guangzhou Brain Hospital</institution><named-content content-type="city">Guangzhou</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0012"><label><sup>12</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Nanjing Brain Hospital</institution><named-content content-type="city">Nanjing</named-content><country country="CN">China</country></aff><aff id="appy12238-aff-0013"><label><sup>13</sup></label><named-content content-type="organisation-division">Department of Psychiatry</named-content><institution>Mental Health Center of Wu Han City</institution><named-content content-type="city">Wuhan</named-content><country country="CN">China</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence<break/>
Xin Yu, MD, National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital, Institute of Mental Health, and the Key Laboratory of Mental Health, Ministry of Health, Peking University, 51 Huayuanbei Road, Haidian District, Beijing 100191, China.<break/>
Tel: +86&#x02010;10&#x02010;82801999<break/>
Fax: +86&#x02010;10&#x02010;62026310<break/>
E&#x02010;mail: <email>yuxin078@163.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><volume>8</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/appy.2016.8.issue-3</issue-id><fpage>241</fpage><lpage>244</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>11</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Australia, Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors Asia&#x02010;Pacific Psychiatry Published by John Wiley &#x00026; Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:APPY-8-241.pdf"/><abstract><title>Abstract</title><sec id="appy12238-sec-0001"><title>Introduction</title><p>This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.</p></sec><sec id="appy12238-sec-0002"><title>Methods</title><p>A multicenter, single&#x02010;arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8&#x02009;weeks. The primary endpoint was &#x02265;50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.</p></sec><sec id="appy12238-sec-0003"><title>Results</title><p>A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved &#x02265;50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.</p></sec><sec id="appy12238-sec-0004"><title>Discussion</title><p>Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="appy12238-kwd-0001">amisulpride</kwd><kwd id="appy12238-kwd-0002">antipsychotic agents/adverse effects</kwd><kwd id="appy12238-kwd-0003">antipsychotic agents/therapeutic use</kwd><kwd id="appy12238-kwd-0004">Chinese</kwd><kwd id="appy12238-kwd-0005">Schizophrenia</kwd></kwd-group><counts><page-count count="4"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>appy12238</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.5 mode:remove_FC converted:20.10.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="appy12238-cit-0000">
<string-name>
<surname>Liang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Dong</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Tang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Xin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Xie</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Z.</given-names>
</string-name>, and <string-name>
<surname>Yu</surname>, <given-names>X.</given-names>
</string-name> (<year>2016</year>) <article-title>The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8&#x02010;week, prospective, open&#x02010;label, multicenter, single&#x02010;arm study</article-title>. <source>Asia&#x02010;Pacific Psychiatry</source>, <volume>8</volume>: <fpage>241</fpage>&#x02013;<lpage>244</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/appy.12238">10.1111/appy.12238</ext-link>.<pub-id pub-id-type="pmid">27020720</pub-id></mixed-citation>
</p></notes></front><body><sec id="appy12238-sec-0005"><title>Introduction</title><p>The majority of extant efficacy and safety data for amisulpride (Solian&#x000ae;) come from studies conducted in Western patients. In Asian populations, only a small number of relevant studies of amisulpride have been reported, and these included relatively small numbers of patients. Furthermore, the data available in Chinese patients are particularly scarce.(Hwang et al., <xref rid="appy12238-bib-0005" ref-type="ref">2003</xref>; Wang et al., <xref rid="appy12238-bib-0011" ref-type="ref">2008</xref>; Ahn et al., <xref rid="appy12238-bib-0001" ref-type="ref">2011</xref>; Lee et al., <xref rid="appy12238-bib-0008" ref-type="ref">2012</xref>) Therapeutic responses to amisulpride have shown significant inter&#x02010;patient variability and will likely differ between geographic regions because of factors such as pharmacogenetics, and local standards of care and dosing recommendations.(Brandl et al., <xref rid="appy12238-bib-0002" ref-type="ref">2014</xref>; Lally &#x00026; MacCabe, <xref rid="appy12238-bib-0007" ref-type="ref">2015</xref>) Therefore, the present study was designed in order to assess the effectiveness and safety of amisulpride in Chinese patients with schizophrenia.</p></sec><sec id="appy12238-sec-0006"><title>Methods</title><sec id="appy12238-sec-0007"><title>Study design and patients</title><p>This 8&#x02010;week, prospective, multicenter, single&#x02010;arm Phase IV study was conducted at 13 psychiatric&#x02010;specialist Tier 1 hospitals in China between 30 October 2012 and 3 December 2013. Adults (18&#x02013;65&#x02009;years) who met the ICD&#x02010;10 criteria for schizophrenia, and had a Positive and Negative Syndrome Scale (PANSS) total score &#x02265;60, were eligible for inclusion. Enrollment included patients treated as inpatients and outpatients. The study was conducted in accordance with the principles of the declaration of Helsinki and received ethical approval from local institutional ethics review boards at all participating centers. Written informed consent was obtained from all study subjects. The study was registered at ClinicalTrials.gov (NCT01795183).</p></sec><sec id="appy12238-sec-0008"><title>Treatment</title><p>After a screening phase, amisulpride tablets (50&#x02009;mg/tablet) were administered orally for 8&#x02009;weeks; dosing and titration were in accordance with the approved Chinese labeling (<ext-link ext-link-type="uri" xlink:href="http://drugs.medlive.cn/drugref/html/15330.shtml">http://drugs.medlive.cn/drugref/html/15330.shtml</ext-link>. Accessed October 2015). In patients switching from other antipsychotics (because of suboptimal treatment response or unacceptable adverse events [AEs]), the dose of the previous medication was gradually reduced upon initiation of amisulpride, with the aim of complete discontinuation within 1&#x02009;week.</p></sec><sec id="appy12238-sec-0009"><title>Measurements</title><p>The primary effectiveness endpoint was a &#x02265;50% decrease in PANSS total score from Baseline to Week 8. Two subgroup analyses were conducted: in treatment&#x02010;naive patients versus patients who were switched to amisulpride, and in patients with predominantly positive versus predominantly negative symptoms. Safety data were continuously monitored from Baseline to the end of the study. Blood samples for prolactin level testing were taken from patients in the morning before breakfast.</p></sec><sec id="appy12238-sec-0010"><title>Statistics</title><p>Using an estimate that 60% of patients would achieve a &#x02265;50% improvement in PANSS total score after 8&#x02009;weeks, enrolment of 300 patients would provide a 95% confidence interval of 53.64% to 66.12%, accounting for a 16% dropout rate.(Kuang et al., <xref rid="appy12238-bib-0006" ref-type="ref">2009</xref>)</p><p>All statistical analyses and treatment effects were tested at a two&#x02010;sided significance level of 0.05. Statistical Analytic System software version 9.2 (SAS Institute, Cary, North Carolina, USA) was used to perform all statistical analyses.</p></sec></sec><sec id="appy12238-sec-0011"><title>Results</title><p>In total, 316 patients were enrolled, and 251 completed the 8&#x02010;week study. Among patients in the effectiveness analysis, 66.8% (197/295) achieved the primary endpoint (Table <xref rid="appy12238-tbl-0001" ref-type="table-wrap">1</xref>). An early clinical response (&#x02265;20% improvement in PANSS total score after 2&#x02009;weeks of treatment) was achieved by 56.6% of patients.</p><table-wrap id="appy12238-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of study results</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Variable</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td rowspan="9" align="left" valign="top" colspan="1">Baseline characteristics (SS; <italic>n</italic>&#x02009;=&#x02009;316)</td><td align="left" valign="top" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">148 (46.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean age (years&#x02009;&#x000b1;&#x02009;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">32.6&#x02009;&#x000b1;&#x02009;11.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean BMI (kg/cm<sup>2</sup>&#x02009;&#x000b1;&#x02009;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">23.1&#x02009;&#x000b1;&#x02009;4.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type of schizophrenia defined by ICD&#x02010;10, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Paranoid</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">192 (60.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Undifferentiated</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">101 (32.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">17 (5.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unspecified</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (1.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Received previous treatment for schizophrenia, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">237 (75.0)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Treatment exposure (SS, <italic>n</italic>&#x02009;=&#x02009;316)</td><td align="left" valign="top" rowspan="1" colspan="1">Mean starting dose of amisulpride, mg &#x000b1; SD</td><td align="center" valign="top" rowspan="1" colspan="1">243.7&#x02009;&#x000b1;&#x02009;115.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean daily dose of amisulpride over 8&#x02010;week study duration, mg&#x02009;&#x000b1;&#x02009;SD<xref ref-type="fn" rid="appy12238-note-0002">&#x02020;</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">678.0&#x02009;&#x000b1;&#x02009;224.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Use of any concomitant medication, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">257 (81.3)</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Effectiveness<xref ref-type="fn" rid="appy12238-note-0003">&#x02021;</xref> (ITT, <italic>n</italic>&#x02009;=&#x02009;295)</td><td align="left" valign="top" rowspan="1" colspan="1">Primary endpoint: &#x02265;50% decrease in PANSS total score from Baseline to Week 8, <italic>n</italic> (%) [95% CI]</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">197 (66.8) [61.1&#x02013;72.1]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Treatment naive patients (<italic>n</italic>&#x02009;=&#x02009;70)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">48 (68.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pre&#x02010;treated patients switching to amisulpride (<italic>n</italic>&#x02009;=&#x02009;225)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">149 (66.2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Predominantly positive symptoms (<italic>n</italic>&#x02009;=&#x02009;266)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">182 (68.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Predominantly negative symptoms (<italic>n</italic>&#x02009;=&#x02009;26)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">13 (50.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Early response: &#x02265;20% decrease in PANSS total score from Baseline to Week 2, <italic>n</italic> (%) [95% CI]</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">167 (56.6) [50.7&#x02013;62.3]</td></tr><tr><td rowspan="11" align="left" valign="top" colspan="1">Safety<xref ref-type="fn" rid="appy12238-note-0004">&#x000a7;</xref> (<italic>n</italic>&#x02009;=&#x02009;316)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;1 AE, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">187 (59.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;1 treatment&#x02010;related AE, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">186 (58.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nervous system, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">107 (33.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Extrapyramidal side effects</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">82 (25.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Akathisia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (4.7)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dystonia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8 (2.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory testing and electrocardiogram, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">93 (29.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Blood prolactin increase (&#x0003e;25&#x02009;ng/mL)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">82 (25.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Weight gain (&#x0003e;7% increase from Baseline)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14 (4.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Endocrine system, <italic>n</italic> (%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">26 (8.2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hyperprolactinemia<xref ref-type="fn" rid="appy12238-note-0005">&#x000b6;</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">26 (8.2)</td></tr></tbody></table><table-wrap-foot><fn id="appy12238-note-0001"><p>AE, adverse event; BMI, body mass index; ICD&#x02010;10, Tenth Revision of the International Classification of Diseases and Related Health Problems; ITT, Intention&#x02010;to&#x02010;Treat, the effectiveness analysis population defined as patients who received at least one dose of study medication and underwent at least one assessment of the primary effectiveness variable; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation; SS, safety analysis population, defined as all patients who received at least one dose of study medication.</p></fn><fn id="appy12238-note-0002"><label>&#x02020;</label><p>
In 305 patients with available data.</p></fn><fn id="appy12238-note-0003"><label>&#x02021;</label><p>
Last observation carried forward.</p></fn><fn id="appy12238-note-0004"><label>&#x000a7;</label><p>
Patients may have reported &#x0003e;1 adverse event.</p></fn><fn id="appy12238-note-0005"><label>&#x000b6;</label><p>
blood prolactin increase with clinical symptoms.</p></fn><fn id="appy12238-note-0006"><p>[Corrections added on 16 May 2016, after first online publication: All occurrences of &#x02018;% (<italic>n</italic>)&#x02019; and the format of its corresponding data have been amended to &#x02018;<italic>n</italic> (%)&#x02019; throughout the above table for consistency.]</p></fn></table-wrap-foot></table-wrap><p>A similar proportion of the treatment&#x02010;naive and previously treated patients achieved a &#x02265;50% decrease in PANSS total score from Baseline to Week 8 (68.6% versus 66.2%) (Table <xref rid="appy12238-tbl-0001" ref-type="table-wrap">1</xref>). Among the 266 patients with predominantly positive symptoms, 68.4% achieved a &#x02265;50% decrease in PANSS total score by Week 8. Of the 26 patients with predominantly negative symptoms, 50.0% achieved a &#x02265;50% decrease in PANSS total score at Week 8.</p><p>A total of nine (3.1%) patients withdrew from the study because of an adverse reaction, and one patient experienced a serious AE (suicide attempt), which the investigator judged was not related to the study treatment. The incidence of drug&#x02010;related, treatment&#x02010;emergent AEs was 58.9% (186/316) (Table <xref rid="appy12238-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="appy12238-sec-0012"><title>Discussion</title><p>The results of this single&#x02010;arm study show that 8&#x02010;week treatment with amisulpride effectively improved the clinical symptoms of Chinese patients with schizophrenia; approximately two thirds (66.8%) of patients achieved a &#x02265;50% decrease in PANSS total score from Baseline to Week 8. In addition, a rapid response to amisulpride treatment was observed in the majority of patients; 56.6% of study subjects achieved a &#x02265;20% improvement in PANSS total score from Baseline to Week 2. Interestingly, results of a subgroup analysis suggested that amisulpride is equally effective for treatment&#x02010;naive schizophrenia patients and those who switch to amisulpride from other antipsychotics.</p><p>Although a direct comparison of this study with previous research is difficult, because of variability in study duration, enrolment criteria, and assessment variables, the effectiveness results broadly support several prior studies conducted in other countries.(Carriere et al., <xref rid="appy12238-bib-0003" ref-type="ref">2000</xref>; Sechter et al., <xref rid="appy12238-bib-0010" ref-type="ref">2002</xref>; Mortimer et al., <xref rid="appy12238-bib-0009" ref-type="ref">2004</xref>) The incidence of extrapyramidal side effects reported in the present study (25.9%) is comparable with two previous reports (23% and 13%) (Carriere et al., <xref rid="appy12238-bib-0003" ref-type="ref">2000</xref>; Colonna et al., <xref rid="appy12238-bib-0004" ref-type="ref">2000</xref>).</p><p>The primary limitation of this study was that patients with predominantly positive symptoms accounted for the majority of the patients included, which may limit the generalizability of the results.</p></sec><sec id="appy12238-sec-0014"><title>Contributorship statements</title><p>All authors drafted or revised the work for intellectual content and approved the final version. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Ying Liang: Conception and design of the work and the acquisition and interpretation of data, analysis of data. Changan Cao: Conception and design of the work and the acquisition and interpretation of data. Cheng Zhu: Conception and design of the work and the acquisition and interpretation of data. Chuanyue Wang: Conception and design of the work and the acquisition and interpretation of data. Congpei Zhang: Conception and design of the work and the acquisition and interpretation of data. Fang Dong: Conception and design of the work and the acquisition and interpretation of data. Fude Yang: Conception and design of the work and the acquisition and interpretation of data, Hong Deng: Conception and design of the work and the acquisition and interpretation of data. Jingjie Yu: Conception and design of the work and the acquisition and interpretation of data. Jisheng Tang: Conception and design of the work and the acquisition and interpretation of data. Lei Su: Conception and design of the work and the acquisition and interpretation of data. Limin Xin: Conception and design of the work and the acquisition and interpretation of data. Ling Hong: Conception and design of the work and the acquisition and interpretation of data. Minglong Gao: Conception and design of the work and the acquisition and interpretation of data. Muni Tang: Conception and design of the work and the acquisition and interpretation of data. Shiping Xie: Conception and design of the work and the acquisition and interpretation of data. Shuiping Lu: Conception and design of the work and the acquisition and interpretation of data. Tiebang Liu: Conception and design of the work and the acquisition and interpretation of data. Xiaojin Xu: Conception and design of the work and the acquisition and interpretation of data. Xijin Wang: Conception and design of the work and the acquisition and interpretation of data. Xuanzi Li: Conception and design of the work and the acquisition and interpretation of data. Xueyi Wang: Conception and design of the work and the acquisition and interpretation of data. Yi Li: Conception and design of the work and the acquisition and interpretation of data. Yong Zhang: Conception and design of the work and the acquisition and interpretation of data. Zhiyu Chen: Conception and design of the work and the acquisition and interpretation of data. Xin Yu: Conception and design of the work and the acquisition and interpretation of data, analysis of data.</p></sec></body><back><ack id="appy12238-sec-0013"><title>Acknowledgments</title><p>Sanofi (China) provided funding for this study and developed and approved the study protocol. No financial or other incentives were given to study participants. Editorial assistance was provided by Jake Burrell of Adelphi Consultech and funded by Sanofi. The authors received sponsorship (AMISU_L_06155) from Sanofi (China) to conduct this study and have no further conflicts of interest.</p></ack><ref-list content-type="cited-references" id="appy12238-bibl-0001"><title>References</title><ref id="appy12238-bib-0001"><mixed-citation publication-type="journal" id="appy12238-cit-0001">
<string-name>
<surname>Ahn</surname>
<given-names>Y.M.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>K.Y.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>C.E.</given-names>
</string-name>, et al. (<year>2011</year>) <article-title>The acute and long&#x02010;term effectiveness of amisulpride in patients with schizophrenia: results of a 12&#x02010;month open&#x02010;label prospective follow&#x02010;up study</article-title>. <source>Hum Psychopharmacol.</source>
<volume>26</volume>, <fpage>568</fpage>&#x02013;<lpage>577</lpage>.<pub-id pub-id-type="pmid">22139601</pub-id></mixed-citation></ref><ref id="appy12238-bib-0002"><mixed-citation publication-type="journal" id="appy12238-cit-0002">
<string-name>
<surname>Brandl</surname>
<given-names>E.J.</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>D.J.</given-names>
</string-name> (<year>2014</year>) <article-title>Pharmacogenetics of antipsychotics</article-title>. <source>Can J Psychiatry</source>
<volume>59</volume>, <fpage>76</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">24881126</pub-id></mixed-citation></ref><ref id="appy12238-bib-0003"><mixed-citation publication-type="journal" id="appy12238-cit-0003">
<string-name>
<surname>Carriere</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Bonhomme</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Lemperiere</surname>
<given-names>T.</given-names>
</string-name> (<year>2000</year>) <article-title>Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double&#x02010;blind study (the Amisulpride Study Group)</article-title>. <source>Eur Psychiatry</source>
<volume>15</volume>, <fpage>321</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">11032464</pub-id></mixed-citation></ref><ref id="appy12238-bib-0004"><mixed-citation publication-type="journal" id="appy12238-cit-0004">
<string-name>
<surname>Colonna</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Saleem</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Dondey&#x02010;Nouvel</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Rein</surname>
<given-names>W.</given-names>
</string-name> (<year>2000</year>) <article-title>Long&#x02010;term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group</article-title>. <source>Int Clin Psychopharmacol.</source>
<volume>15</volume>, <fpage>13</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">10836281</pub-id></mixed-citation></ref><ref id="appy12238-bib-0005"><mixed-citation publication-type="journal" id="appy12238-cit-0005">
<string-name>
<surname>Hwang</surname>
<given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S.M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>H.J.</given-names>
</string-name>, et al. (<year>2003</year>). <article-title>Amisulpride versus risperidone in the treatment of schizophrenic patients: a double&#x02010;blind pilot study in Taiwan</article-title>. <source>J Formos Med Assoc.</source>
<volume>102</volume>, <fpage>30</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">12684609</pub-id></mixed-citation></ref><ref id="appy12238-bib-0006"><mixed-citation publication-type="journal" id="appy12238-cit-0006">
<string-name>
<surname>Kuang</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X.</given-names>
</string-name> (<year>2009</year>) <article-title>A preliminary clinical study of amisulpride in treatment of forty patients with schizophrenia</article-title>. <source>J Psychiatry</source>
<volume>22</volume>, <fpage>180</fpage>&#x02013;<lpage>181</lpage>.</mixed-citation></ref><ref id="appy12238-bib-0007"><mixed-citation publication-type="journal" id="appy12238-cit-0007">
<string-name>
<surname>Lally</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>MacCabe</surname>
<given-names>J.H.</given-names>
</string-name> (<year>2015</year>) <article-title>Antipsychotic medication in schizophrenia: a review</article-title>. <source>Br Med Bull.</source>
<volume>114</volume>, <fpage>169</fpage>&#x02013;<lpage>179</lpage>.<pub-id pub-id-type="pmid">25957394</pub-id></mixed-citation></ref><ref id="appy12238-bib-0008"><mixed-citation publication-type="journal" id="appy12238-cit-0008">
<string-name>
<surname>Lee</surname>
<given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>S.W.</given-names>
</string-name>, <string-name>
<surname>Koo</surname>
<given-names>B.H.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>T.Y.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>K.H.</given-names>
</string-name> (<year>2012</year>) <article-title>A 6&#x02010;week, randomized, multicentre, open&#x02010;label study comparing efficacy and tolerability of amisulpride at a starting dose of 400&#x02009;mg/day versus 800&#x02009;mg/day in patients with acute exacerbations of schizophrenia</article-title>. <source>Clin Drug Investig.</source>
<volume>32</volume>, <fpage>735</fpage>&#x02013;<lpage>745</lpage>.</mixed-citation></ref><ref id="appy12238-bib-0009"><mixed-citation publication-type="journal" id="appy12238-cit-0009">
<string-name>
<surname>Mortimer</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Loo</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Peuskens</surname>
<given-names>J.</given-names>
</string-name> (<year>2004</year>) <article-title>A double&#x02010;blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia</article-title>. <source>Int Clin Psychopharmacol.</source>
<volume>19</volume>, <fpage>63</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">15076013</pub-id></mixed-citation></ref><ref id="appy12238-bib-0010"><mixed-citation publication-type="journal" id="appy12238-cit-0010">
<string-name>
<surname>Sechter</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Peuskens</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fleurot</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Rein</surname>
<given-names>W.</given-names>
</string-name>, <string-name>
<surname>Lecrubier</surname>
<given-names>Y.</given-names>
</string-name> (<year>2002</year>) <article-title>Amisulpride vs. risperidone in chronic schizophrenia: results of a 6&#x02010;month double&#x02010;blind study</article-title>. <source>Neuropsychopharmacology</source>
<volume>27</volume>, <fpage>1071</fpage>&#x02013;<lpage>1081</lpage>.<pub-id pub-id-type="pmid">12464464</pub-id></mixed-citation></ref><ref id="appy12238-bib-0011"><mixed-citation publication-type="journal" id="appy12238-cit-0011">
<string-name>
<surname>Wang</surname>
<given-names>Y.T.</given-names>
</string-name>, <string-name>
<surname>Chiu</surname>
<given-names>N.Y.</given-names>
</string-name>, <string-name>
<surname>Jou</surname>
<given-names>S.H.</given-names>
</string-name>, et al. (<year>2008</year>) <article-title>Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone</article-title>. <source>Int J Psychiatry Clin Pract.</source>
<volume>12</volume>, <fpage>180</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">24931656</pub-id></mixed-citation></ref></ref-list></back></article>